Inmaculada Casas

A study published in the journal Science Translational Medicine shows the results of a phase 1 trial of a new broad-spectrum influenza vaccine. Prepared in the form of nanoparticles containing the H1 hemagglutinin stem-a region that is often conserved in different subtypes of the virus-the vaccine was generally well tolerated by participants, who showed only mild side effects such as tenderness and headaches. The prototype generated an antibody response to group 1 influenza viruses in all age groups.

In the last few days, data, preprints, press releases and even graphs have started to arrive via social media showing how neutralising antibodies against the omicron variant behave. These studies are preliminary and we will have to wait and see how these lab data translate into the real world.